• May 02, 2005 | Webcast

    Surrogate Endpoints for Clinical Trials

    Clifford J. Rosen, M.D., Theresa Kehoe, M.D., Henry Bone, M.D., Steven Cummings, M.D., Gayle Lester, Ph.D., Joan McGowan, Ph.D., Harry Genant, M.D., Pierre Delmas, M.D., Ph.D.
    Skeletal Physiology, Molecular Cellular and Genetic Determinants of Bone Structure and Formation, Integrative Physiology of the Skeleton

    Moderator:

    Clifford J. Rosen, M.D., Maine Center for Osteoporosis Research, St. Joseph Hospital, Bangor, Maine, USA

    Speakers:

    Surrogate Endpoints for Clinical Trials: FDA Perspective
    Theresa Kehoe, M.D., Division of Metabolic and Endocrine Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA

    Incorporation of New Surrogates into Clinical Trials
    Henry Bone, M.D., F.A.C.P., Michigan Bone and Mineral Clinic, Detroit, Michigan, USA

    Validating New Surrogate Markers for Fracture
    Steven R. Cummings, M.D., Department of Medicine and Epidemiology, California Pacific Medical Center Research Institute, San Francisco, California, USA

    New Opportunities for Collaborations and Funding
    Gayle E. Lester, Ph.D., Musculoskeletal Diseases Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, Maryland, USA

    Joan A. McGowan, Ph.D.
    Musculoskeletal Diseases Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, Maryland, USA

    This meeting was sponsored by the American Society for Bone and Mineral Research (ASBMR) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

    Supported by educational grants from Eli Lilly and Company, NPS Pharmaceuticals, Merck & Co., Inc., The Alliance for Better Bone Health (Procter & Gamble Pharmaceuticals and sanofi-aventis, US), Novartis Pharmaceuticals Corporation, Amgen, Inc. and Wyeth Pharmaceuticals

    Length: 125 minutes

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Policies and Procedures for more details